Nervous System Active Pharmaceutical Ingredients Market Trends

Growth Drivers

Growing Popularity of Personalized Medicines- The healthcare system is paying more attention to precision medicine since it enables more individualized treatments. Nervous system active pharmaceutical ingredients are utilized in personalized medicine approaches, which is estimated to drive market growth.
Rising Focus on Mental Health- The pandemic also contributed to a greater focus on mental health, which has resulted in a rise in demand for mental health treatments including nervous system active pharmaceutical ingredients.

Challenges

Availability of Counterfeit Drugs– The availability of substandard counterfeit medicines is expected to hinder market growth during the forecast period. For instance, counterfeit drugs are available everywhere around the world and customers find them cost-effective and convenient.
Shortage of the Required Ingredients

Lack of Awareness of Medication

Nervous System Active Pharmaceutical Ingredients Market: Key Insights

Base Year	2023
Forecast Year	2024-2036
CAGR	4.7%
Base Year Market Size (2023)	USD 209.4 Billion
Forecast Year Market Size (2036)	USD 380.44 Billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of nervous system active pharmaceutical ingredients is assessed at USD 218.26 Billion.

The nervous system active pharmaceutical ingredients market size was over USD 209.4 Billion in 2023 and is expected to reach USD 380.44 Billion by the end of 2036, witnessing around 4.7% CAGR during the forecast period i.e., between 2024-2036. The growing presence of chronic diseases across the globe and the growing geriatric population are the major factors driving the growth of the market.

Asia Pacific industry is estimated to be the second largest share of 30% by 2036, led by low labor costs in the region.

Pfizer, Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Shenzhen Hepalink Pharmaceutical Co. Ltd., GSK plc, F. Hoffmann-La Roche Ltd, Cipla Inc., Eli Lilly and Company, Novartis AG, Teva Pharmaceutical Industries Ltd.

Nervous System Active Pharmaceutical Ingredients Market Trends